Guidance
Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: 2025
Guidance development process
How we develop NICE medical technologies guidance
If a technology is recommended for use, the specific recommendations are not intended to limit use of other relevant technologies that may offer similar advantages. If the technology is recommended for use in research, the recommendations are not intended to preclude the use of the technology but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.
This guidance replaces NICE's medical technologies guidance on GreenLight XPS for treating benign prostatic hyperplasia (MTG29).